| | | Single nucleotide variant (synonymous variant +1 more) | not provided +2 more | |
| | | Single nucleotide variant (missense variant +1 more) | not provided +2 more | |
| | | Single nucleotide variant (3 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (5 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (5 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (3 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (missense variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (5 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (5 prime UTR variant +2 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (5 prime UTR variant +2 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (synonymous variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to +1 more | GConflicting classifications of pathogenicity |
| | | Single nucleotide variant (intron variant) | not provided +1 more | |
| | | Single nucleotide variant (synonymous variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (synonymous variant +1 more) | not provided +1 more | |
| | | Single nucleotide variant (synonymous variant +1 more) | not provided +1 more | |
| | | Single nucleotide variant (3 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (3 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (3 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (3 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (3 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (3 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (3 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (3 prime UTR variant +1 more) | not provided +1 more | |
| | HTRA2, LOXL3 (T449I +3 more) | Single nucleotide variant (missense variant +2 more) | not provided +1 more | |
| | | Single nucleotide variant (synonymous variant +3 more) | Parkinson disease 13, autosomal dominant, susceptibility to +2 more | |
| | | Single nucleotide variant (synonymous variant +3 more) | not provided +1 more | GConflicting classifications of pathogenicity |
| | | Single nucleotide variant (intron variant) | not provided +1 more | GConflicting classifications of pathogenicity |
| | | Single nucleotide variant (synonymous variant +2 more) | not provided +1 more | GConflicting classifications of pathogenicity |
| | | Single nucleotide variant (synonymous variant +2 more) | Parkinson disease 13, autosomal dominant, susceptibility to +1 more | GConflicting classifications of pathogenicity |
| | | Single nucleotide variant (synonymous variant +1 more) | HTRA2-related disorder +2 more | |
| | | Single nucleotide variant (intron variant) | Parkinson disease 13, autosomal dominant, susceptibility to +1 more | |
| | | Single nucleotide variant (intron variant) | not provided +1 more | |
| | | Single nucleotide variant (synonymous variant +1 more) | not provided +3 more | |
| | | Single nucleotide variant (missense variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (missense variant +1 more) | HTRA2-related disorder +2 more | |
| | | Single nucleotide variant (5 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (5 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (5 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (5 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (5 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (5 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (5 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (5 prime UTR variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (5 prime UTR variant +2 more) | not specified +1 more | |
| | | Single nucleotide variant (5 prime UTR variant +2 more) | Parkinson disease 13, autosomal dominant, susceptibility to +1 more | |
| | | Single nucleotide variant (5 prime UTR variant +2 more) | Parkinson disease 13, autosomal dominant, susceptibility to +1 more | |
| | | Single nucleotide variant (missense variant +1 more) | Parkinson disease 13, autosomal dominant, susceptibility to | |
| | | Single nucleotide variant (missense variant +1 more) | 3-methylglutaconic aciduria type 8 +2 more | |
| | | Single nucleotide variant (missense variant +3 more) | not provided +1 more | |